Although sublingual immunotherapy (SLIT) has become an effective treatment option for many allergies, about 20-30 percent of patients don’t respond to SLIT for Japanese cedar pollinosis — a highly common disease. In a recent study, scientists reported that a specific variant of the HLA-DPB1 gene is associated with poor response to this treatment, highlighting the potential of this and similar genes as relevant biomarkers in clinical practice for predicting one’s responsiveness to allergen immunotherapy.
Lesen Sie weiter auf: Is it working? Scientists say gene variant indicates effectiveness of immunotherapy for allergies
Quelle: ScienceDaily | Allergy
Titelbild/Grafik by ScienceDaily News
Kommentare und FragenMöchten Sie zu diesem Artikel ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- Longer duration of exclusive breastfeeding has protective effect on childhood asthma
- Researchers discover immune system changes that support peanut allergy remission in children
- Caesarean births not linked to increased risk of food allergy during infancy
- Can a messenger substance considered to be inflammatory alleviate asthma symptoms?
- Researchers studying ways to ease asthma symptoms caused by seasonal allergies
- A novel painless and reliable allergy test
- Longer, more intense allergy seasons could result from climate change
- Is it working? Scientists say gene variant indicates effectiveness of immunotherapy for allergies
- Microneedle approach to address peanut allergy shows promise in mice
- Molds and yeasts common in daycares — could cause chronic asthma and allergy